key: cord-0955615-0otuz51o authors: Han, Xiaoyu; Fan, Yanqing; Alwalid, Osamah; Zhang, Xin; Jia, Xi; Zheng, Yuting; Shi, Heshui title: Fibrotic Interstitial Lung Abnormalities at 1-year Follow-up CT after Severe COVID-19 date: 2021-07-27 journal: Radiology DOI: 10.1148/radiol.2021210972 sha: 001801ec3fa543b1e452a52061b7d1f64c2f5f29 doc_id: 955615 cord_uid: 0otuz51o Fibrotic interstitial lung abnormalities in severe COVID-19 survivors depicted on 6-month CT scans were persistent on 1-year CT scans and were negatively correlated with the lung diffusion capacity. Given the large scale of COVID-19 pandemic worldwide, lung sequelae post-COVID-19 is a major concern to all populations. Our previous study (1) showed that about one third of severe COVID-19 survivors had lung "fibrotic-like" changes [fibrotic interstitial lung abnormalities (ILAs) according to Fleischner Society Glossary (2)] on 6 months follow up. However, whether these fibrotic ILAs changes are permanent, progressive or reversible remained unclear and little is known about the one-year sequela of COVID-19. The purpose of this study was to assess the chest CT changes of fibrotic ILAs at one-year follow-up in COVID-19 survivors. This prospective study was approved by the Ethics Commission of Wuhan Jin Yin-tan Hospital and Wuhan Union Hospital. All participants remained anonymous, and written informed content was acquired by June 1 st ,2020. A total of 71 participants (41 men, 30 women; mean age, 57±10 years) who harbored lung sequelae (40 cases with fibrotic ILAs [previously described as fibrotic-like changes], 31 cases without fibrotic ILAs, including ground-glass opacification (GGO), consolidation or reticular abnormalities) at six-month follow up in our previous study (1) were invited to this one-year follow-up study. Nine cases were excluded due to refusal to participate in the study. Finally, 62 participants (34 men, 28 women; mean age, 57±10 years; 35 cases with fibrotic ILAs, 27 cases without fibrotic ILAs) were prospectively enrolled in this study (Flowchart of inclusion is shown in Figure E1 ). The World Health Organization's (WHO) interim guidance diagnostic criteria for adults with severe COVID-19 pneumonia were used (3). Within 1 week of the follow-up CT scans, 57 I n p r e s s 5 participants (32 men, 25 women; mean age, 57±10 years) underwent standard pulmonary function testing (PFT) at six months while 53 participants (31 men, 21 women; mean age, 57 ±10 years)had PFT tests at one year. The severity of the diffusing lung capacity drop was assessed using a standardized grading system (4): Normal, >75% -140%; mild, 60% -75%; moderate, 40% -59%; and severe, <40%. All 62 participants underwent one year follow-up CT examinations using the same scanners (SOMATOM Definition AS+ or SOMATOM Perspective) as the 6-month CT scans. CT images obtained at 6-month and one-year were reviewed side-by-side in random order by three senior cardiothoracic radiologists (HSS, YQF, and XZ with 31, 13 and 8 years of experience in thoracic radiology, respectively). After independent evaluation, discussion and consensus resolved any disagreement. For each patient, CT features according to the Fleischner Society glossary were assessed and recorded (Appendix E1). A semiquantitative CT score (Appendix E1) was used to quantify the extent of pulmonary abnormalities (all lesions, GGO, consolidation, interstitial lung abnormalities, and fibrotic interstitial lung abnormalities and traction bronchiectasis). The final study group consisted of 62 participants (34 men, 28 women; mean age, 57±10 years; Compared with the 6-month CT scans, decrease in the CT scores of all lesions, GGO, reticular pattern and ILAs (all p < .05) were observed on one-year CT scans. However, CT scores of the fibrotic ILAs and traction bronchiectasis showed no differences between the two CT scans (p = .40, p=.75). Regarding PFT findings, DLCO% abnormality was mostly and consistently mild, with no severe grading. Although the DLCO% value slightly improved over time (85±12% vs 89±19%), no differences were found between the two occasions PFT and the severity of DLCO% (all p＞.05, Table 1 ). At the one-year follow up, 9/62 (15%) participants suffered from exertional dyspnea, of which, 7/9 (78%) participants had fibrotic ILAs on CT. There were still 13/53 (25%) participants with abnormal pulmonary diffusion on one-year PFT seen particularly in those with fibrotic ILAs (11/13, 85%, Table E1 ). Besides, a negative correlation was found between the score of fibrotic ILAs and DLCO% (r=-.35, p=.01) at one year follow up. This study shows that fibrotic ILAs was a common and persistent sequela on one-year followup CT after severe COVID-19. Recent autopsy studies found that diffuse alveolar damage (DAD) is the primary pathologic finding in patients with fatal COVID-19, which is indistinguishable from other causes of DAD (5) . Since the fibrotic phase of DAD could be laid I n p r e s s 7 down in the process of lung injury due to the failure of removal of alveolar collagen (6), the fibrotic ILAs detected in our study could be part of DAD, which could also be similar to other forms of post-viral fibrotic changes such as those occurring after SARS-CoV infection. Although a reversible CT evidence of lung fibrosis was noted in the early convalescence stage of SARS-CoV infection (7), lung fibrotic changes on CT images persisted in SARS-CoV survivors until 1 year after discharge (8) . Furthermore, a long-term follow-up SARS-CoV study (9) found that the proportion of lung fibrosis could remain stable from one-year to 15-year follow-up. Similarly, our results confirmed that fibrotic ILAs were persisting on one-year follow up, which indicate that fibrotic diseases in late stage might be irreversible, though whether the findings represent actual pathologic fibrosis remain to be confirmed with lung biopsy. There are some limitations to this study, including the small sample size and the lack of confirmatory pathological testing, as well as the lack of quantitative analyses of lung parenchyma. We conclude that interstitial lung abnormalities were found to be persistent at one-year followup CT scans in severe COVID-19 survivors, which were correlated with a reduction in the diffusion capacity of carbon monoxide. These findings need to be confirmed by further investigations on larger population. Table Table E1 . Comparison of the ongoing symptoms and lung function between participants with and without fibrotic ILA. Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance Using and interpreting carbon monoxide diffusing capacity (DLCO) correctly Diffuse alveolar damage (DAD) resulting from coronavirus disease 2019 Infection is Morphologically Indistinguishable from Other Causes of DAD Acute respiratory distress syndrome Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: preliminary experience Dynamic changes of serum SARS-coronavirus IgG, pulmonary function and radiography in patients recovering from SARS after hospital discharge Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study We would like to thank all colleagues for helping us during the current study and all the selfless volunteers who participated in the study. We are also very grateful to many members of the frontline medical staff for their selfless dedication and heroic dedication in the face of this outbreak, despite the potential threat to their own lives and the lives of their families. Interstitial lung abnormalities were defined as affecting > 5% of the lung on CT scan and parenchymal abnormalities that fall into the spectrum of ILAs include nondependent GGO or reticular abnormalities, non-emphysematous cysts, traction bronchiectasis, and honeycombing. The details of the CT scoring system are as follows: Each lobe was assigned a score from 0 to 5 (0: no involvement; 1: <5% involvement; 2: 5-25% involvement; 3: 26-50% involvement; 4: 51-75% involvement; 5: >75% involvement). The CT scores for the five lung lobes were added to obtain the total CT score, which measured the overall lung involvement, ranging from